Affiliate(s):
Roche (terminated 12/09)   
In December 2009, Roche Holding terminated development of RG1507. The decision was based on the clinical data to date, the large number of molecules targeting the same pathway presently in development, and the prioritization of the Roche portfolio, and not on any safety concerns.

In December 2007, initiation of a phase II clinical trial in sarcoma triggered a $500,000.milestone payment to Genmab.

In June 2002, Roche and Genmab agreed on a broad expansion of a collaboration for the creation and development of human antibody therapeutic products for life-threatening and debilitating diseases. Roche also made an equity investment in Genmab totaling $20 million at a price of DKK 180 per share. This expanded program involves a number of new disease targets from Roche. Genmab expects to initiate approximately 15 new projects in the coming year across a number of therapeutic areas. The program is coordinated by Roche's Pharmaceutical Research and will expand the company's significant commitment to the development of biologicals as innovative new medicines. Under the current agreement Roche has access to Genmab's antibody development capabilities as well as its preclinical and clinical development capabilities. Genmab will receive milestones as well as royalty payments on successful products. In certain circumstances, Genmab could obtain rights to develop products based on disease targets identified by Roche. If all goals are reached, the value of the collaboration could be as high as $100 million.

Aveo Pharmaceuticals   
In June 2010, the initiation of a phase II clinical trial in non-small sell lung cancer triggered an $8.5 million milestone payment by Merck to Aveo.

In September 2008, initiation of a phase III clinical trial with AV-299 triggered a $3.0 million milestone payment from Schering-Plough to Aveo Pharmaceuticals.

In April 2007, Aveo Pharmaceuticals entered into an exclusive worldwide agreement with Schering-Plough to develop and commercialize AV-299. It is expected to enter clinical trials in early 2008. Aveo’s Human Response Prediction (HRP) platform will be used to guide the clinical development of AV-299. Under the terms of the agreement, Aveo will have primary responsibility for clinical development of AV-299 through proof-of-concept in man. Aveo will also apply its HRP platform during a multi-year translational research program designed to discover biomarker profiles of patients most likely to benefit from treatment with AV-299. Results of this research will be used to design the optimal clinical development plan for AV-299. AVEO retains the option to co-promote AV-299 in the USA for certain oncology indications. In consideration of the exclusive worldwide license, Aveo will receive a $7.5 million upfront payment and a $10 million equity investment from Schering-Plough. Schering-Plough will fund all R&D expenses. Milestone payments for the successful development and commercialization of AV-299, if all approvals in multiple indications and all sales milestones are achieved, could exceed $460 million. Upon commercialization, Aveo is eligible to receive royalties on net sales.

Current as of: August 04, 2010